Recruitment of β-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells

Molecular Endocrinology

Volumn 18, Issue 10, 2004, Pages 2388-2401

  Masiello, David ^a   Chen, Shao Yong ^a   Xu, Youyuan ^a   Verhoeven, Manon C ^a,b   Choi, Eunis ^a   Hollenberg, Anthony N ^a   Balk, Steven P ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BETA CATENIN; BICALUTAMIDE; CELL NUCLEUS RECEPTOR; CYPROTERONE ACETATE; FLUTAMIDE; HYDROXYFLUTAMIDE; MIFEPRISTONE; NUCLEAR RECEPTOR COREPRESSOR; PROSTATE SPECIFIC ANTIGEN; REPRESSOR PROTEIN; STEROID RECEPTOR COACTIVATOR 1; THYMINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION;

BETA CATENIN; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DIHYDROTESTOSTERONE; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSFECTION;

ANIMALIA;

EID: 5044238220     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0436     Document Type: Article

References (86)

1. Quigley CA, De Bellis A, Marschke KB, el Awady MK, Wilson EM, French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev [Erratum (1995) 16:546] 16:271-321
2. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J 1999 Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 69:307-313
3. Belandia B, Parker MG 2003 Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 114: 277-280
4. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736
5. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
6. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
7. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143
8. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:87-94
9. Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357
10. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675
11. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948-4952
12. Xu J, Li Q 2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17:1681-1692
13. Simental JA, Sar M, Lane MV, French FS, Wilson EM 1991 Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266: 510-518
14. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO 1991 Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404
15. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO 1998 Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol Endocrinol 12:1172-1183
16. Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR 1998 Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12:302-313
17. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B 1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 19:6085-6097
18. He B, Kemppainen JA, Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994
19. Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990
20. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J 1997 Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36:1052-1064
21. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219-37225
22. Ikonen T, Palvimo JJ, Janne OA 1997 Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 272:29821-29828
23. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM 1999 Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 13:440-454
24. Chang CY, McDonnell DP 2002 Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 16:647-660
25. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
26. Berrevoets CA, Umar A, Brinkmann AO 2002 Antiandrogens: selective androgen receptor modulators. Mol Cell Endocrinol 198:97-103
27. Kuil CW, Berrevoets CA, Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 270: 27569-27576
28. Wong C, Kelce WR, Sar M, Wilson EM 1995 Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270:19998-20003
29. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP 1997 Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3:1383-1388
30. Wilding G, Chen M, Gelmann EP 1989 Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115
31. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
32. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515
33. Poyet P, Labrie F 1985 Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42: 283-288
34. Kemppainen JA, Lane MV, Sar M, Wilson EM 1992 Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267:968-974
35. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705
36. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
37. Zhang X, Jeyakumar M, Petukhov S, Bagchi MK 1998 A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 12:513-524
38. Hu X, Lazar MA 1999 The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93-96
39. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP 2002 Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 16:1492-1501
40. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16:661-673
41. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD 2003 Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 278:5052-5061
42. Truica CI, Byers S, Gelmann EP 2000 β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709-4713
43. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z 2002 Linking β-catenin to androgen-signaling pathway. J Biol Chem 277:11336-11344
44. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC 2002 The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277:17933-17943
45. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME 2002 Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 277:20702-20710
46. Chesire DR, Ewing CM, Gage WR, Isaacs WB 2002 In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 21:2679-2694
47. Chesire DR, Isaacs WB 2002 Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene 21:8453-8469
48. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP 2003 β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23:1674-1687
49. List HJ, Smith CL, Martinez E, Harris VK, Danielsen M, Riegel AT 2000 Effects of antiandrogens on chromatin remodeling and transcription of the integrated mouse mammary tumor virus promoter. Exp Cell Res 260: 160-165
50. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP 2002 AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol 16:85-99
51. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E 1992 The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669
52. Berns EM, de Boer W, Mulder E 1986 Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 9:247-259
53. Warriar N, Page N, Koutsilieris M, Govindan MV 1994 Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Prostate 24:176-186
54. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP 1998 The nuclear compressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18:1369-1378
55. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai MJ, O'Malley BW 2002 Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 99: 7940-7944
56. Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzel T, Renkawitz R 2002 RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem 277:26238-26243
57. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP 2003 A direct β-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem 278:30828-30834
58. Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM 1999 Effects of new 17α-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer 81:622-630
59. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM 2000 Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60:6630-6640
60. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153
61. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21: 2673-2678
62. Li H, Kim JH, Koh SS, Stallcup MR 2004 Synergistic effects of coactivators GRIP1 and β-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem 279:4212-4220
63. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC 2003 Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22:5602-5613
64. Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A 2003 Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 213:79-85
65. Song LN, Coghlan M, Gelmann EP 2004 Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 18:70-85
66. Berrevoets CA, Umar A, Trapman J, Brinkmann AO 2004 Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR). Biochem J 379(Pt 3):731-738
67. Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, Chambon P, Gronemeyer H 1992 A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 255:206-209
68. Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P, Gronemeyer H 1992 Switching agonistic, antagonistic, and mixed transcriptional responses to 11 β-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 6:2071-2078
69. Cadepond F, Ulmann A, Baulieu EE 1997 RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48:129-156
70. Honer C, Nam K, Fink C, Marshall P, Ksander G, Chatelain RE, Cornell W, Steele R, Schweitzer R, Schumacher C 2003 Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol 63: 1012-1020
71. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL 2002 Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364
72. Terouanne B, Nirde P, Rabenoelina F, Bourguet W, Sultan C, Auzou G 2003 Mutation of the androgen receptor at amino acid 708 (Gly->Ala) abolishes partial agonist activity of steroidal antiandrogens. Mol Pharmacol 63: 791-798
73. Hurlstone A, Clevers H 2002 T-cell factors: turn-ons and turn-offs. EMBO J 21:2303-2311
74. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B 2004 Glycogen synthase kinase-3β activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145:2941-2949
75. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K 2002 Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21:4099-4107
76. Voeller HJ, Truica CI, Gelmann EP 1998 β-Catenin mutations in human prostate cancer. Cancer Res 58: 2520-2523
77. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB 2000 Detection and analysis of β-catenin mutations in prostate cancer. Prostate 45:323-334
78. Sharma M, Chuang WW, Sun Z 2002 Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 277:30935-30941
79. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S 2001 Tumor suppressor PTEN inhibits nuclear accumulation of β-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153:1161-1174
80. De la TA, Rubin MA, Chen MW, Vacherot F, De Medina SG, Burchardt M, Buttyan R, Chopin D 2003 β-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9:1801-1807
81. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E 1989 The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem 34:307-310
82. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
83. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP 2001 Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276:13442-13451
84. Cohen RN, Brzostek S, Kim B, Chorev M, Wondisford FE, Hollenberg AN 2001 The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Mol Endocrinol 15:1049-1061
85. Markus SM, Taneja SS, Logan SK, Li W, Ha S, Hittelman AB, Rogatsky I, Garabedian MJ 2002 Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus. Mol Biol Cell 13: 670-682
86. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP 2002 Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277:26321-26326